Holen Sie sich die Stockscreener-App
16.75
4.10%
0.66
Handel nachbörslich:
16.62
-0.13
-0.78%
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Learn to Evaluate (SPRY) using the Charts - news.stocktradersdaily.com
ARS Pharmaceuticals | 6/18/25 - ktnv.com
Asthma Market to Expand Significantly by 2034, States - openPR.com
Asthma Market to Expand Significantly by 2034, States DelveInsight Report | GSK, AB Science, Areteia Therapeutics, ARS Pharma, AstraZeneca, Pieris Pharma, Sanofi, Cumberland Pharma, Genentech - Barchart.com
ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy - MSN
Jim Cramer on ARS Pharmaceuticals: “It’s a Great Flier” - Insider Monkey
Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey
ARS Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Long Term Trading Analysis for (SPRY) - news.stocktradersdaily.com
Bank of America Corp DE Has $1.70 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals - WBFF
Ameriprise Financial Inc. Buys 36,928 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
BNP Paribas Financial Markets Purchases New Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ProShare Advisors LLC Buys 3,436 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $354,000 Stock Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Deutsche Bank AG Increases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
Neffy provides needle-free relief to those with allergic reactions - KOIN.com
ARS brings relief to your whole home - KOIN.com
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
ARS Pharmaceuticals Leadership Takes Stage at 3 Major Investment Conferences This June - Stock Titan
(SPRY) Trading Advice - news.stocktradersdaily.com
D. E. Shaw & Co. Inc. Decreases Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals: neffy - WCIV
Exploring US High Growth Tech Stocks In May 2025 - simplywall.st
Brent Saunders Sells 120,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus
Expert Dr. Chase shares insights on Neffy for summer allergy season - KOKH
FY2025 EPS Estimates for SPRY Cut by Cantor Fitzgerald - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by The Manufacturers Life Insurance Company - Defense World
Needle-Free Emergency Epinephrine Now Available for Pediatric Patients - Dermatology Advisor
Leerink Partnrs Has Bearish Outlook for SPRY Q2 Earnings - Defense World
William Blair Brokers Lower Earnings Estimates for SPRY - Defense World
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Up 10.8% – Still a Buy? - Defense World
Price T Rowe Associates Inc. MD Reduces Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q1 2025 Earnings Call Transcript - MSN
ARS Pharmaceuticals targets 80% commercial coverage for neffy in 2025 while expanding pediatric reach - MSN
Ars Pharmaceuticals’ Neffy Launch Boosts Market Prospects - TipRanks
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates - MSN
What You Need To Know About The ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analyst Downgrade Today - Yahoo Finance
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15% - simplywall.st
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launc - GuruFocus
Dimensional Fund Advisors LP Has $2.07 Million Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals Reports Strong Q1 2025 Performance - TipRanks
SPRY Reports Q1 Revenue Surpassing Expectations, Preps for Key M - GuruFocus
ARS Pharmaceuticals (SPRY) Reports Strong Start with Neffy Launch in Q1 2025 - GuruFocus
ARS Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q1 2025 revenue beats forecast - Investing.com Nigeria
Transcript : ARS Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ARS Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Estimates at $8.0M, EPS Misses at -$0.35 - GuruFocus
ARS Pharmaceuticals Q1 Operating Income USD -37.177 Million - marketscreener.com
ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq
ARS Pharmaceuticals' Q1 Net Loss Widens, Revenue Tops Estimates - marketscreener.com
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray) - The Manila Times
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
ARS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ARS Pharmaceuticals Reports First Quarter 2025 Financial - GlobeNewswire
ARS Pharma Q1 Earnings: First Needle-Free Epinephrine Spray Hits $7.8M Revenue, 57% Insurance Coverage - Stock Titan
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):